// App-Quantinova.ai

: 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Researchers

Presenter

  • Sattva S. Neelapu

Principal Investigators

  • Alison R. Sehgal

  • Narendranath Epperla

  • Matthew Ulrickson

  • Emanuel Bachy

  • Pashna N. Munshi

  • Carla Casulo

  • David G. Maloney

  • Sven De Vos

  • Ran Reshef

  • Lori A. Leslie

  • Olalekan O. Oluwole

  • Ibrahim Yakoub-Agha

  • Rashmi Khanal

  • Joseph D. Rosenblatt

  • Jiali Yan

  • Qinghua Song

  • Weixin Peng

  • Christine Lui

  • Jacob Wulff

  • Rhine R. Shen

  • Soumya Poddar

  • Harry Miao

  • Sara Beygi

  • Caron A. Jacobson

Medical Centers

  • Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

  • Fox Chase Cancer Center, Philadelphia, PA

  • Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Vanderbilt University Medical Center, Nashville, TN

  • UPMC Hillman Cancer Center, Pittsburgh, PA

  • John Theurer Cancer Center, Hackensack, NJ

  • Banner MD Anderson Cancer Center, Gilbert, AZ

  • University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • CHU de Lille, Univ Lille, INSERM U, Infinite, Lille, France

  • Fred Hutchinson Cancer Research Center, SEATTLE, WA

  • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH

  • Dana-Farber Cancer Institute, Boston, MA

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

  • University of Rochester Medical Center - James P. Wilmot Cancer Center, Rochester, NY

Locations

  • United States

  • France

Companies

  • Kite Pharma, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Axicabtagene ciloleucel

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved